Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide

Hybridoma

Volumn 18, Issue 2, 1999, Pages 149-157

  Ota, Akemi ^a   Tanaka Taya, Keiko ^b   Ueda, Shigeharu ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIGEN; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 8H10; PEPTIDE; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CROSS REACTION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PURIFICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0032994081     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1999.18.149     Document Type: Article

References (31)

1. Wills JW and Craven RC: Form, function, and use of retroviral Gag proteins. AIDS 1991;5:639-654.
2. Yu X, Yuan X, Matsuda Z, Lee T, and Essex M: The matrix protein of human Immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol 1992;66:4966-4971.
3. Dorfman T, Mammano F, Haseltine WA, and Gottlinger HG: Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1994;68:1689-1696.
4. Truong C, Brand D, Mallet F, Roingeard P, Brunet S, and Barin F: Assembly and immunogenicity of chimeric Gag-Env proteins derived from the human immunodeficiency virus type 1. AIDS Res Hum Retro 1995;12:291-301.
5. Kattenbeck B, Rohrhofer A, Neidrig M, Wolf H, and Modrow S: Defined amino acid in the gag proteins of human immunodeficiency virus type 1 are functionally active during virus assembly. Intervirology 1996;39:32-39.
6. Reicin AS, Ohagen A, Yin L, Hoglund S, and Goff SP: The role of gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. J Virol 1996;70:8645-8652.
7. Ono A, Huang M, and Freed EO: Characterization of human immunodeficiency virus type 1 matrix revertants: Effects on virus assembly. Gag processing, and Env incorporation into virions. J Virol 1997;71:4409-4418.
8. Kiernan RE, Ono A, Englund G, and Freed EO: Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol 1998;72:4116-4126.
9. Gallina A, Mantoan G, Rindi G, and Milanesi G: Influence of MA internal sequences, but not of the myristylated N-terminus sequence, on the budding site of HIV-1 gag protein. Biochem Biophys Res Comm 1994;204:1031-1038.
10. Zhou W and Resh MD: Differential membrane binding of the human immunodeficiency virus type 1 matrix protein. J Virol 1996;70:8540-8548.
11. Spearman P, Horton R, Ratner L, and Kuli-Zade I: Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism. J Virol 1997;71:6582-6592.
12. Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubei A, Spitz L, Lewis P, Goldfarb D, Emerman M, and Stevenson M: A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993;365:666-669.
13. Gulizia J, Dempsey MP, Sharova N, Bukrinsky MI, Spitz L, Goldfarb D, and Stevenson M: Reduced nuclear import of human immunodeficiency virus type 1 preintegration complexes in the presence of a prototypic nuclear targeting signal. J Virol 1994; 68:2021-2025.
14. Gallay P, Stitt V, Mundy C, Oettinger M, and Trono D: Role of the Karyopherin Pathway in human immunodeficiency virus type 1 nuclear import. J Virol 1996;70:1027-1032.
15. Schwedler U, Kornbluth RS, and Trono D: The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci USA 1994;91: 6992-6996.
16. Fouchier RAM, Meyer BE, Simon JHM, Fischer U, and Malim MH: HIV-1 infection of non-dividing cells: Evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO 1997;16:4531-4539.
17. Burnette B, Yu G, and Felsted RL: Phosphorylation of HIV-1 gag proteins by protein kinase C. J Biol Chem 1993;268:8698-8703.
18. Gallay P, Swingler S, Aiken C, Trono D: HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell 1995;80:379-388.
19. Bukrinskaya AG, Ghorpade A, Heinzinger NK, Smithgall TE, Lewis RE, and Stevenson M: Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA. Proc Natl Acad Sci USA 1996;93:367-371.
20. Swingler S, Gallay P, Camaur D, Song J, Abo A, and Trono D: The nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix. J Virol 1997;71:4372-4377.
21. Choudhury AM, Yamada O, Wakamiya N, and Kurimura T: A prospective study on correlation between the decrease in anti-p17 antibody level and progression to AIDS in asymptomatic carriers of HIV. Microbiol Immunol 1992;36:833-840.
22. Chargelegue D, Stanley CM, O'toole CM, Colvin BT, and Steward MW: The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression. Clin Exp Immunol 1995;99:175-181.
23. Eugen-Olsen J, Koppelhus U, Andresen L, Nielsen JO, and Hofmann B: A recombinant HIV gag p17 protein suppresses the function of normal T cells. Biochem Soc Trans 1997;25:220s.
24. Liu X, Ota A, Watanabe M, Ueda S, Saitoh A, Shinagawa H, Nakata A, Kurimura T, Wang X, Zhao Y, Kondo K, Seki J, Miyake S, Sakato N, and Fujio H: Three antigenic regions in p17 of human immunodeficiency virus type 1 (HIV-1) revealed by mouse monoclonal antibodies and human antibodies in HIV-1 carrier sera. Microbial Immunol 1995;39:775.
25. Ota A, Liu X, Fujio H, Sakato N, and Ueda S: Random expression of human immunodeficiency virus-1 (HIV-1) p17(epitopes) on the surface of the HIV-1 infected cell. Hybridoma 1998:17:73-75.
26. La Rosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dressman GR, Boswell RN, Shadduck P, et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990;249:932-935.
27. Feng S, Chen JK, Yu H, Simon JA, and Schreiber SL: Two binding orientations for peptides to the Src SH3 domain: Development of a general model for SH3-ligand interactions. Science 1994; 266:1241-1247.
28. Kato T, Kurita K, Kawanami T, and Sasaki H: Detection of a 23 kDa human brain protein that shares epitope(s) with the 17 kDa core protein of human immunodeficiency virus (HIV). Neurosci Lett 1994;181:134-136.
29. Kato T, Suzuki J, Daimon M, Sasaki H, and Ishikawa K: Antibodies to the HIV-1 p17 protein cross-react with human superoxide dismutase-2. Biochem Biophys Res Comm 1997;230:184-187.
30. Lyden TW, Johnson PM, Mwenda JM, Rote NS: Expression of endogenous HIV-1 crossreactive antigens within normal human extravillous trophoblast cells. J Reprod Immuno 1995;28:233-245.
31. Buratti E, Tisminetzky SG, D'agaro P, and Baralle FE: A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE. J Virol 1997;71:2457-2462.